Literature DB >> 31691154

Increasing Blood Pressure by Greater Splanchnic Nerve Stimulation: a Feasibility Study.

Anisha Bapna1, Christopher Adin2, Zoar J Engelman1, Marat Fudim3,4.   

Abstract

The splanchnic vascular compartment is the major reservoir for intravascular blood volume, and dysregulation of the compartment was implicated in a series of cardiovascular conditions. We explored feasibility and effectiveness of an implantable cuff system on the greater splanchnic nerve (GSN) in healthy canines for short- and long-term neuromodulation to affect the circulation. Five mongrel hounds underwent minimally invasive right-sided unilateral GSN cuff placement. All animals underwent same day GSN stimulation and repeat stimulation at 9-30 days. Stimulation parameter optimization was conducted both acutely and chronically. Parameters ranged from 1-250 Hz, 0.25 mA-35 mA, 0.1-0.5 ms, and 30-s pulse duration. Two animals were survived for 9 days and 3 animals for 30 days. Stimulation of the right GSN increased mean arterial blood pressure by 36.9 mmHg ± 13.4 (p < 0.0001), central venous pressure by 6.9 mmHg ± 1.7 (p < 0.0001), and mean pulmonary arterial pressure by 6.3 mmHg ± 2.0 (p < 0.0001). Peak effects were observed within 30 s, and magnitude of effects was comparable between stimulation cycles (p = 0.4). Stimulation-induced changes in hemodynamics were independent of afferent nerve fibers (pain response) or the adrenal gland. Necropsy showed no evidence of nerve damage on histologic studies up to 30 days after implantation. GSN stimulation via an implanted nerve cuff provided a reproducible and rapid method to increase arterial, central venous, and pulmonary arterial pressures. The neuromodulation cuff was well tolerated and elicited a response up to 30 days after implantation. The clinical application of GSN stimulation as a tool to change central and peripheral cardiovascular hemodynamics needs to be explored.

Entities:  

Keywords:  Hemodynamics; Neuromodulation; Splanchnic nerve

Mesh:

Year:  2019        PMID: 31691154     DOI: 10.1007/s12265-019-09929-7

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  6 in total

Review 1.  Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond.

Authors:  Marat Fudim; Muhammad Shahzeb Khan; Anousheh Awais Paracha; Kenji Sunagawa; Daniel Burkhoff
Journal:  Circ Heart Fail       Date:  2022-03-15       Impact factor: 8.790

Review 2.  Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations.

Authors:  Marat Fudim; Piotr P Ponikowski; Daniel Burkhoff; Mark E Dunlap; Paul A Sobotka; Jeroen Molinger; Manesh R Patel; G Michael Felker; Adrian F Hernandez; Sheldon E Litwin; Barry A Borlaug; Anisha Bapna; Horst Sievert; Vivek Y Reddy; Zoar J Engelman; Sanjiv J Shah
Journal:  Eur J Heart Fail       Date:  2021-05-09       Impact factor: 17.349

3.  Neurocapillary-Modulation.

Authors:  Niranjan Khadka; Marom Bikson
Journal:  Neuromodulation       Date:  2020-12-19

4.  Splanchnic Nerve Ablation for Volume Management in Heart Failure.

Authors:  Marat Fudim; Zoar J Engelman; Vivek Y Reddy; Sanjiv J Shah
Journal:  JACC Basic Transl Sci       Date:  2022-04-04

5.  Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort.

Authors:  Marat Fudim; Peter S Fail; Sheldon E Litwin; Tamaz Shaburishvili; Parag Goyal; Scott L Hummel; Barry A Borlaug; Rajeev C Mohan; Ravi B Patel; Sumeet S Mitter; Liviu Klein; Krishna Rocha-Singh; Manesh R Patel; Vivek Y Reddy; Daniel Burkhoff; Sanjiv J Shah
Journal:  Eur J Heart Fail       Date:  2022-05-29       Impact factor: 17.349

Review 6.  Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies.

Authors:  Ana Jorbenadze; Marat Fudim; Felix Mahfoud; Phillip B Adamson; Tarek Bekfani; Rolf Wachter; Horst Sievert; Piotr P Ponikowski; John G F Cleland; Stefan D Anker
Journal:  ESC Heart Fail       Date:  2021-05-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.